MovDisordV3, PascalFrancis, Curation, bibRecord, 001932

Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases

Identifieur interne : 001932 ( PascalFrancis/Curation ); précédent : 001931; suivant : 001933

Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases

Auteurs : Martin J. Hecht [Allemagne] ; Henning Stolze [Allemagne] ; Matthias Auf Dem Brinke [Allemagne] ; Ralf Giess [Allemagne] ; Thoams Treig [Allemagne] ; Martin Winterholler [Allemagne] ; Jorg Wissel [Allemagne]

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0133665

Descripteurs français

Pascal (Inist)
- Hypertonie spastique, Paraplégie spasmodique héréditaire de Strümpell-Lorrain, Pathologie du système nerveux, Bontoxilysin, Etude cas, Traitement.

English descriptors

KwdEn :
- Bontoxilysin, Case study, Hereditary spastic paraplegia, Nervous system diseases, Spasticity, Treatment.

Abstract

Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT-A) might also be considered for patients with HSP. We report the effect of BoNT-A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT-A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT-A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT-A injections in HSP.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases`
A11	`01`	`1`		`@1 HECHT (Martin J.)`
A11	`02`	`1`		`@1 STOLZE (Henning)`
A11	`03`	`1`		`@1 DEM BRINKE (Matthias Auf)`
A11	`04`	`1`		`@1 GIESS (Ralf)`
A11	`05`	`1`		`@1 TREIG (Thoams)`
A11	`06`	`1`		`@1 WINTERHOLLER (Martin)`
A11	`07`	`1`		`@1 WISSEL (Jorg)`
A14	`01`			`@1 Department of Neurology, University of Erlangen-Nuremberg @2 Erlangen @3 DEU @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, BKH Kaufbeuren @3 DEU @Z 1 aut.`
A14	`03`			`@1 Department of Neurology, University of Kiel @2 Kiel @3 DEU @Z 2 aut.`
A14	`04`			`@1 Department of Neurology, Diako Hospital @2 Flensburg @3 DEU @Z 2 aut.`
A14	`05`			`@1 Department of Neurological Rehabilitation @2 Bad Wildungen @3 DEU @Z 3 aut.`
A14	`06`			`@1 Department of Neurology, Henriettenstiftung @2 Hannover @3 DEU @Z 4 aut.`
A14	`07`			`@1 Neurological Rehabilitation Centre, Ernst-Moritz-Arndt University @2 Greifswald @3 DEU @Z 5 aut.`
A14	`08`			`@1 Neurological Rehabilitation Centre, Schwarzwaldkliniken @2 Bad Krozingen @3 DEU @Z 5 aut.`
A14	`09`			`@1 Department of Neurology, Rummelsberger Kliniken @2 Schwarzenbruck @3 DEU @Z 6 aut.`
A14	`10`			`@1 Department of Neurological Rehabilitation, Beelitz Heilstiitten @2 Beelitz @3 DEU @Z 7 aut.`
A17	`01`	`1`		`@1 German Spasticity Education Group @3 DEU`
A20				`@1 228-233`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000175066510110`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 13 ref.`
A47	`01`	`1`		`@0 08-0133665`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT-A) might also be considered for patients with HSP. We report the effect of BoNT-A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT-A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT-A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT-A injections in HSP.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17E`
C03	`01`	`X`	`FRE`	`@0 Hypertonie spastique @5 01`
C03	`01`	`X`	`ENG`	`@0 Spasticity @5 01`
C03	`01`	`X`	`SPA`	`@0 Hipertonia espástica @5 01`
C03	`02`	`X`	`FRE`	`@0 Paraplégie spasmodique héréditaire de Strümpell-Lorrain @5 02`
C03	`02`	`X`	`ENG`	`@0 Hereditary spastic paraplegia @5 02`
C03	`02`	`X`	`SPA`	`@0 Paraplejía espasmódica hereditaria Strümpell-Lorrain @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Bontoxilysin @2 FE @2 FR @5 09`
C03	`04`	`X`	`ENG`	`@0 Bontoxilysin @2 FE @2 FR @5 09`
C03	`04`	`X`	`SPA`	`@0 Bontoxilysin @2 FE @2 FR @5 09`
C03	`05`	`X`	`FRE`	`@0 Etude cas @5 10`
C03	`05`	`X`	`ENG`	`@0 Case study @5 10`
C03	`05`	`X`	`SPA`	`@0 Estudio caso @5 10`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 11`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 11`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 11`
C07	`01`	`X`	`FRE`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Metalloendopeptidases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Peptidases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`04`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`04`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`05`	`X`	`FRE`	`@0 Pathologie du muscle strié @5 37`
C07	`05`	`X`	`ENG`	`@0 Striated muscle disease @5 37`
C07	`05`	`X`	`SPA`	`@0 Músculo estriado patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 39`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 39`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 39`
C07	`07`	`X`	`FRE`	`@0 Trouble du tonus @5 40`
C07	`07`	`X`	`ENG`	`@0 Muscle tonus alteration @5 40`
C07	`07`	`X`	`SPA`	`@0 Trastorno tono muscular @5 40`
C07	`08`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 41`
C07	`08`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`08`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`09`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`09`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`09`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`10`	`X`	`FRE`	`@0 Maladie héréditaire @5 43`
C07	`10`	`X`	`ENG`	`@0 Genetic disease @5 43`
C07	`10`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 43`
C07	`11`	`X`	`FRE`	`@0 Pathologie de la moelle épinière @5 44`
C07	`11`	`X`	`ENG`	`@0 Spinal cord disease @5 44`
C07	`11`	`X`	`SPA`	`@0 Médula espinal patología @5 44`
C07	`12`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 45`
C07	`12`	`X`	`ENG`	`@0 Central nervous system disease @5 45`
C07	`12`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 45`
N21				`@1 077`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001387

Links to Exploration step

Pascal:08-0133665

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases</title>
<author><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Erlangen-Nuremberg</s1>
<s2>Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, BKH Kaufbeuren</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, University of Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Diako Hospital</s1>
<s2>Flensburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Dem Brinke, Matthias Auf" sort="Dem Brinke, Matthias Auf" uniqKey="Dem Brinke M" first="Matthias Auf" last="Dem Brinke">Matthias Auf Dem Brinke</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurological Rehabilitation</s1>
<s2>Bad Wildungen</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Giess, Ralf" sort="Giess, Ralf" uniqKey="Giess R" first="Ralf" last="Giess">Ralf Giess</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Henriettenstiftung</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Neurological Rehabilitation Centre, Ernst-Moritz-Arndt University</s1>
<s2>Greifswald</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Neurological Rehabilitation Centre, Schwarzwaldkliniken</s1>
<s2>Bad Krozingen</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Winterholler, Martin" sort="Winterholler, Martin" uniqKey="Winterholler M" first="Martin" last="Winterholler">Martin Winterholler</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Rummelsberger Kliniken</s1>
<s2>Schwarzenbruck</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Wissel, Jorg" sort="Wissel, Jorg" uniqKey="Wissel J" first="Jorg" last="Wissel">Jorg Wissel</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Neurological Rehabilitation, Beelitz Heilstiitten</s1>
<s2>Beelitz</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0133665</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0133665 INIST</idno>
<idno type="RBID">Pascal:08-0133665</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001387</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001932</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases</title>
<author><name sortKey="Hecht, Martin J" sort="Hecht, Martin J" uniqKey="Hecht M" first="Martin J." last="Hecht">Martin J. Hecht</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Erlangen-Nuremberg</s1>
<s2>Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, BKH Kaufbeuren</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, University of Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Diako Hospital</s1>
<s2>Flensburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Dem Brinke, Matthias Auf" sort="Dem Brinke, Matthias Auf" uniqKey="Dem Brinke M" first="Matthias Auf" last="Dem Brinke">Matthias Auf Dem Brinke</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurological Rehabilitation</s1>
<s2>Bad Wildungen</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Giess, Ralf" sort="Giess, Ralf" uniqKey="Giess R" first="Ralf" last="Giess">Ralf Giess</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Henriettenstiftung</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Treig, Thoams" sort="Treig, Thoams" uniqKey="Treig T" first="Thoams" last="Treig">Thoams Treig</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Neurological Rehabilitation Centre, Ernst-Moritz-Arndt University</s1>
<s2>Greifswald</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Neurological Rehabilitation Centre, Schwarzwaldkliniken</s1>
<s2>Bad Krozingen</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Winterholler, Martin" sort="Winterholler, Martin" uniqKey="Winterholler M" first="Martin" last="Winterholler">Martin Winterholler</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Rummelsberger Kliniken</s1>
<s2>Schwarzenbruck</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Wissel, Jorg" sort="Wissel, Jorg" uniqKey="Wissel J" first="Jorg" last="Wissel">Jorg Wissel</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Neurological Rehabilitation, Beelitz Heilstiitten</s1>
<s2>Beelitz</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Case study</term>
<term>Hereditary spastic paraplegia</term>
<term>Nervous system diseases</term>
<term>Spasticity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hypertonie spastique</term>
<term>Paraplégie spasmodique héréditaire de Strümpell-Lorrain</term>
<term>Pathologie du   système nerveux</term>
<term>Bontoxilysin</term>
<term>Etude cas</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT-A) might also be considered for patients with HSP. We report the effect of BoNT-A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT-A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT-A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT-A injections in HSP.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HECHT (Martin J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STOLZE (Henning)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DEM BRINKE (Matthias Auf)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GIESS (Ralf)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>TREIG (Thoams)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WINTERHOLLER (Martin)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WISSEL (Jorg)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Erlangen-Nuremberg</s1>
<s2>Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, BKH Kaufbeuren</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, University of Kiel</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Diako Hospital</s1>
<s2>Flensburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurological Rehabilitation</s1>
<s2>Bad Wildungen</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Henriettenstiftung</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Neurological Rehabilitation Centre, Ernst-Moritz-Arndt University</s1>
<s2>Greifswald</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Neurological Rehabilitation Centre, Schwarzwaldkliniken</s1>
<s2>Bad Krozingen</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Neurology, Rummelsberger Kliniken</s1>
<s2>Schwarzenbruck</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Neurological Rehabilitation, Beelitz Heilstiitten</s1>
<s2>Beelitz</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>German Spasticity Education Group</s1>
<s3>DEU</s3>
</fA17>
<fA20><s1>228-233</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000175066510110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>13 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0133665</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT-A) might also be considered for patients with HSP. We report the effect of BoNT-A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT-A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT-A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT-A injections in HSP.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17E</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Hypertonie spastique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Spasticity</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hipertonia espástica</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Paraplégie spasmodique héréditaire de Strümpell-Lorrain</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hereditary spastic paraplegia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Paraplejía espasmódica hereditaria Strümpell-Lorrain</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Case study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du muscle strié</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble du tonus</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Muscle tonus alteration</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno tono muscular</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>43</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Pathologie de la moelle épinière</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Spinal cord disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Médula espinal patología</s0>
<s5>44</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>45</s5>
</fC07>
<fN21><s1>077</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001932 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001932 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:08-0133665
   |texte=   Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases

Botulinum Neurotoxin Type A Injections Reduce Spasticity in Mild to Moderate Hereditary Spastic Paraplegia : Report of 19 Cases

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri